| SC 13D | 2024-04-01 | BAKER BROS. ADVISORS LP | Kymera Therapeutics, Inc. | 5,997,706 | 9.8% | EDGAR |
| SC 13G/A | 2024-02-14 | Avoro Capital Advisors LLC | Kymera Therapeutics, Inc. | 3,775,000 | 6.8% | EDGAR |
| SC 13G/A | 2024-02-13 | VANGUARD GROUP INC | Kymera Therapeutics, Inc. | 3,997,564 | 6.7% | EDGAR |
| SC 13G/A | 2024-02-12 | PRICE T ROWE ASSOCIATES INC /MD/ | Kymera Therapeutics, Inc. | 5,340,414 | 9.6% | EDGAR |
| SC 13G/A | 2024-02-12 | PRICE T ROWE ASSOCIATES INC /MD/ | Kymera Therapeutics, Inc. | 5,999,256 | 10.1% | EDGAR |
| SC 13G/A | 2024-02-09 | Atlas Venture Fund X, L.P. | Kymera Therapeutics, Inc. | 4,968,114 | 8.4% | EDGAR |
| SC 13G/A | 2024-02-08 | WELLINGTON MANAGEMENT GROUP LLP | Kymera Therapeutics, Inc. | 4,815,558 | 8.7% | EDGAR |
| SC 13G/A | 2024-01-29 | BlackRock Inc. | Kymera Therapeutics, Inc. | 3,566,611 | 6.4% | EDGAR |
| SC 13G/A | 2024-01-23 | STATE STREET CORP | Kymera Therapeutics, Inc. | - | 3.4% | EDGAR |
| SC 13G/A | 2024-01-10 | BAKER BROS. ADVISORS LP | Kymera Therapeutics, Inc. | 5,995,928 | 10.8% | EDGAR |
| SC 13D/A | 2024-01-09 | BIOTECHNOLOGY VALUE FUND L P | Kymera Therapeutics, Inc. | 3,206,616 | 5.5% | EDGAR |
| SC 13D/A | 2023-06-05 | VERTEX PHARMACEUTICALS INC / MA | Kymera Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-02-14 | PRICE T ROWE ASSOCIATES INC /MD/ | Kymera Therapeutics, Inc. | 4,379,159 | 8.0% | EDGAR |
| SC 13G/A | 2023-02-14 | Redmile Group, LLC | Kymera Therapeutics, Inc. | 2,673,837 | 4.9% | EDGAR |
| SC 13G/A | 2023-02-14 | Atlas Venture Fund X, L.P. | Kymera Therapeutics, Inc. | 5,066,925 | 9.2% | EDGAR |
| SC 13G | 2023-02-14 | Avoro Capital Advisors LLC | Kymera Therapeutics, Inc. | 3,850,000 | 7.0% | EDGAR |
| SC 13G | 2023-02-14 | BAKER BROS. ADVISORS LP | Kymera Therapeutics, Inc. | 2,879,825 | 5.2% | EDGAR |
| SC 13G/A | 2023-02-09 | VANGUARD GROUP INC | Kymera Therapeutics, Inc. | 3,660,307 | 6.7% | EDGAR |
| SC 13G | 2023-02-08 | STATE STREET CORP | Kymera Therapeutics, Inc. | - | 5.2% | EDGAR |
| SC 13G/A | 2023-02-06 | WELLINGTON MANAGEMENT GROUP LLP | Kymera Therapeutics, Inc. | 4,591,089 | 8.4% | EDGAR |